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Background: Mucoperiosteal fl ap surgeries (MFS) are carried out to provide access to the 
alveolar bone and root surfaces in several clinical situations. Nevertheless, they lead to a variable 
degree of alveolar bone resorption. Raloxifene is an agonist in bone, and acts inhibiting bone 
loss. 
Objective: To evaluate the effect of raloxifene in preventing alveolar bone resorption after 
MFS using an experimental model of mouse mandibles.
Methods: MFS was performed on the buccal aspect of the left side of the mandible (BL) in 
20 male CF1 Musdomesticus mice divided into two groups with the same number of animals: the 
experimental group was treated once daily with raloxifene injections (3 mg/kg), and the placebo 
group was treated with daily injections of the vehicle. The buccal aspects of right hemimandibles 
were used as controls (BR). Mandibles were removed, defl eshed and stained with toluidine blue in 
a stereomicroscope. Digital images were obtained and the alveolar bone loss was measured (mm²) 
using an image analysis software. 
Results: The BL area exhibited signifi cantly more bone loss (Student t test; p < 0.01) when 
compared to the BR area, in both groups. No statistically signifi cant difference was observed 
between the experimental and the placebo groups. 
Conclusion: In this study, raloxifene did not inhibit alveolar bone resorption following MFS 
in male mice. 
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Efeito do raloxifeno sobre reabsorção óssea alveolar após cirurgia 
de retalho mucoperiosteal em camundongos
RESUMO
Introdução: Cirurgias de retalho mucoperiosteal (CRM) são realizadas para permitir 
acesso ao osso alveolar e à superfície radicular em várias situações clínicas. No entanto, elas 
levam a um grau variável de reabsorção óssea alveolar. O raloxifeno tem ação agonista em 
tecido ósseo e atua inibindo perda óssea. 
Objetivo: Avaliar o efeito do raloxifeno na prevenção de reabsorção óssea alveolar após 
CRM usando o modelo experimental de mandíbulas de camundongos. 
Métodos: Foram realizadas CRMs na face vestibular, lado esquerdo, das mandíbulas 
(VE) de 20 camundongos CF1 Musdomesticus machos, divididos em dois grupos com mesmo 
número de animais: o grupo experimental foi tratado uma vez ao dia com injeções de raloxifeno 
(3 mg/kg), e o grupo placebo foi tratado uma vez ao dia com injeções do veículo. A face 
vestibular do lado direito da hemimandíbula foi usada como controle (BD). As mandíbulas 
foram removidas, dissecadas e coradas com azul de toluidina sob um estereomicroscópio. 
Imagens digitais foram obtidas e a perda óssea alveolar foi medida (mm²) usando um software 
de análise de imagens. 
Resultados: A área VE exibiu perda óssea signifi cativamente maior (teste t de Student; p 
< 0,01) quando comparada com a área BD, em ambos os grupos. Não foi observada diferença 
estatisticamente signifi cativa entre os grupos experimental e placebo. 
Conclusão: Neste estudo, o raloxifeno não inibiu a reabsorção óssea alveolar após CRM 
em camundongos machos. 
Palavras-chave: Cloridrato de Raloxifeno; Perda do Osso Alveolar; Cirurgia, Oral.
INTRODUCTION
Bone is a dynamic tissue with high remodeling capacity in response to the 
body’s metabolic requirements. Under normal circumstances, bone volume and mass 
are held constant by bone resorption and apposition processes (1). Nevertheless, 
some factors, including surgical bone exposure, may lead to some imbalance in 
these mechanisms. 
In dentistry, surgical access to the alveolar bone is routinely conducted as 
part of different treatment approaches, including restoration, periodontal treatment, 
rehabilitation, endodontic treatment, and in the surgical removal of teeth and/or 
pathological processes. During the dissection process, the periosteum is detached 
from the alveolar bone, leading to a resorptive phase due to the stimulation offered 
by osteoclastic activity and loss of bone crest (2-4). In rodent mandibles, resorption is 
also observed after surgery (4,5).
Alveolar bone volume reduction may interfere with the success of oral 
rehabilitation treatments. Therefore, loss of this bone tissue should be prevented (6). 
The use of systemic or local drugs in the prevention of bone resorption has been studied 
using animal models (7-16). 
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Raloxifene, a selective estrogen receptor modulator, is an agonist to the human 
skeleton. The compound has been shown to act as an antiresorption drug by reducing 
biochemical markers of bone remodeling and preserving bone mineral density in the 
lumbar spine and femur neck, with signifi cant reduction in the occurrence of new 
fractures. In addition, raloxifene is an antagonist to endometrial and mammary tissues 
(17,18). The preventive effect of raloxifene on the expression of selective bone turnover 
markers has also been observed during the alveolar healing process in female rats 
submitted to ovariectomy surgery (15,19,20).
This study aims to evaluate the effect of raloxifene in preventing alveolar bone 
resorption after mucoperiosteal fl ap surgery (MFS) using an experimental model of 
mouse mandibles (5).
MATERIALS AND METHODS
This study was approved by the Research Ethics Committee of Universidade 
Luterana do Brasil (ULBRA). 
A total of 20 3-month-old male CF1 mice (Musdomesticus) weighing 30 g on 
average were used in this study. Animals were obtained from the colonies maintained 
by state-owned research institution Fundação Estadual de Produção e Pesquisa em 
Saúde. Mice were randomly divided into two experimental groups, consisting of 10 
mice each, all undergoing MFS. The fi rst group (experimental group, EG) was treated 
with raloxifene injections; the second group (placebo group, PG) was given injections 
of the vehicle used in raloxifene dilutions.
Animals were maintained in individual sterilized plastic cages (Beira Mar, São 
Paulo, SP, Brazil) with an iron cover and solid bottom during the experiment. Sterilized 
bedding (Vet-Sul, Porto Alegre, RS, Brazil) was provided. Mice consumed standard 
food (Nutrival, CR-1, Nutrival Nutrients, Curitiba, PR, Brazil) and distilled water ad 
libitum. Standard conditions of light (12-hour light/12-hour dark cycle) and temperature 
(20°C) were kept during the experiment. The experiment was conducted under proper 
ventilation and all animals were monitored daily.
Experimental procedure
Initially, mice of both groups were weighed and anesthetized using intramuscular 
ketamine 100 g/L (Dopalen, Agribrands do Brazil, Paulina, Brazil) + 2% aqueous 
solution of 2-(2,6-xilidine)-5,6-dihydro-4-H-1,3-thiazine hydrochloride (Rompun, 
Bayer S.A., São Paulo, Brazil) at a 1:1 ratio in a dosage of 1.0 mL/kg. The mucosa 
was separated from the underlying bone after an incision at the marginal gingiva with 
a small elevator and then immediately readapted without any suture (4,5,7,10-13). The 
mucoperiosteal fl ap was performed on the buccal aspect of the left side of the lower 
left molars in a procedure that took approximately 40 seconds; the right side was used 
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as control (CG). Animals received only water during the initial 24 hours, to avoid 
displacement of the fl ap.
Mice in the EG were treated with subcutaneous injections of raloxifene 
(Raloxifenchloridrate, Eli Lilly, Brazil) (3mg/kg) dissolved in 100 μL of olive oil, 
daily, throughout the experimental period. The PG received the vehicle (100 μL 
olive oil/mice) (Figueira da Foz, Portugal), also daily (8,10). Animals were weighed 
daily before the injections to calculate the correct dose. Twenty-one days after the 
surgical procedure, animals were euthanized by means of cervical dislocation (4) 
under anesthesia.
Under a surgical stereomicroscope (M900, D F Vasconcelos, São Paulo, Brazil), 
mandibles were sectioned in the midline, defl eshed, and all the organic material was 
removed with the help of sodium hypochlorite (Biodinâmica Química e Farmacêutica 
Ltda., Ibiporã, Brazil). Specimens were then stored in 10% buffered formalin for 12 
hours (21-23). Each hemimandible was stained with 1% toluidine blue to disclose the 
root-exposed area. Limits of enamel, cementum and evident bone were observed in 
a stereomicroscope (Stemi SV6, Carl Zeiss, Inc., USA) under magnifi cation (x3.2), 
using standardized position (24) and light. Images were digitally captured (Pixera 
Professional, Pixera, San Jose, USA).
Bone loss analysis
Bone loss was measured by a single blind, calibrated examiner using image analysis 
software (Image Tool, UTHSCA, Texas, USA). Two independent measurements were 
conducted with an interval of 1 week between them, in order to allow reproducibility 
analysis. In the present study, intra-examiner and trans-experiment reproducibility values 
(95% confi dence interval) were represented by the means of differences between the 
pairs of measurements of alveolar bone loss (ABL), and ranged between -0.03 mm2 
and 0.03 mm2.
In the buccal aspect, the area of the ABL was measured in the fi rst molar, whereas 
in the lingual aspect, the area of ABL was measured in the fi rst and second molars using 
the reference points proposed by Tatakis and Guglielmoni (23) and modifi ed by Hilgert 
et al. (25). The ABL area in the lingual aspect was defi ned as follows: mesially, by the 
mesial edge (cementoenamel junction [CEJ] to the alveolar bone) of the mesial root of 
the fi rst molar; distally, by the distal edge (CEJ to the alveolar bone) of the distal root 
of the second molar; coronally, by three points on each of the two molar teeth (two 
points defi ned by the position of the CEJ on the mesial and distal aspects of the tooth 
and one defi ned by the most apical position of the CEJ on the tooth surface); apically, 
by the most apical position of the alveolar bone on the fi rst and second root surfaces 
(Figure 1). Results are presented in square millimeters (mm²).
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FIGURE 1 – Landmarks used to defi ne the alveolar bone loss area. Connecting all points together represents 
the area of interest. A) Left side, buccal aspect; B) Left side, lingual aspect. 
Statistical analysis
The Student t test for independent samples was used to assess the presence 
of signifi cant differences in respect to alveolar bone loss between mice treated 
with raloxifene and control mice. Furthermore, the Student t test was also used to 
check for intragroup differences (e.g., in BL and BR ABL areas of mice within each 
group). The value set to reject the null hypothesis was p ≤ 0.05. All analyses were 
performed using the Statistical Package for the Social Sciences (SPSS) version 12.0 
for Windows®.
RESULTS
Bone resorption was observed 3 weeks after MFS. ABL was signifi cantly greater 
in the operated area (BL) (Student t test; p < 0.01) when compared to the control side 
(BR) (Table 1). 
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TABLE 1 – Alveolar bone loss area (mm²) in the buccal and lingual sides (both left and right) of the mandible, in 
the control (n = 10) and experimental (n = 10) groups, 21 days after mucoperiosteal fl ap surgery.
 95%CI
 Mean Lower limit Upper limit
BR area (control)*
Control 0.41 0.07 0.75
Experimental 0.34 0.16 0.52
Total 0.37 0.10 0.64
BL area (test)*
Control 0.60 0.14 1.06
Experimental 0.62 -0.16 1.40
Total 0.61 -0.01 1.33
LR area
Control 0.93 0.41 1.45
Experimental 0.98 0.62 1.34
Total 0.96 0.54 1.38
LL area
Control 1.05 0.49 1.61
Experimental 0.96 0.40 1.52
Total 1.00 0.46 1.54
95%CI = 95% confi dence interval; BR = buccal right; BL = buccal left; LR = lingual right; LL = lingual left.
* Statistically signifi cant difference between the operated area (BL) and the control area (BR) (Student t test).
Bone loss did not vary signifi cantly when EG and CG were compared (Figure 2). 
Bone loss was observed (CG vs. EG, respectively) in BL: 0.60±0.23 mm2 vs. 0.62±0.39 
mm2 (p = 0.91); in BR: 0.41±0.17 mm2 vs. 0.34±0.09 mm2 (p=0.69); in LL: 1.05±0.27 
mm2 vs. 0.96±0.28 mm2 (p=0.47); and in LR: 0.93±0.26 mm2 vs. 0.98±0.18 mm2 (p=0.59) 
(Figure 3).
FIGURE 2 – Alveolar bone loss: A) left side, lingual, placebo group; B) left side, lingual, experimental group; C) 
left side, buccal, placebo group; D) left side, buccal, experimental group. 
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FIGURE 3 – Mean alveolar bone loss (in mm²) in the control and experimental groups, right and left aspects, 
lingual and vestibular sides, 10 and 21 days after mucoperiosteal fl ap surgery. BR = buccal right; BL = buccal 
left; LR = lingual right; LL = lingual left.
No weight variation was observed in animals throughout the experimental 
period.
DISCUSSION
The present study evaluated the effect of raloxifene in terms of inhibiting ABL 
after MFS in mice. Under the experimental circumstances here described, raloxifene 
was not able to prevent or even reduce bone resorption. To our knowledge, this is one 
of the fi rst studies to assess whether raloxifene affects bone resorption using a rodent 
model in male mice. 
In the present study, an experimental model of MFS was used to induce ABL in 
mouse mandibles, as different studies have reported bone resorption due to bone exposure 
by fl ap displacement (3,5,7). Yaffe et al. (4) conducted a study with rats and observed 
considerable bone remodeling after MFS in maxillary bones. In mice, this process is 
sex-independent (5). These studies are in agreement with the results shown in the present 
experiment, as ABL was signifi cantly greater in the operated side (BL) when compared 
to the control side (BR).
Bone resorption may interfere negatively with the success of oral rehabilitation 
therapies. Therefore, the search for drugs and treatments that can prevent or minimize 
ABL is an important fi eld of periodontal research. Raloxifene, a selective estrogen 
receptor modulator used in osteoporosis treatment and prophylaxis was tested for its 
role in bone resorption. The drug mimics the effects of estrogen in the bone, with the 
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added benefi ts of not stimulating the uterine endometrium and reducing the risk of breast 
cancer and the incidence of coronary events and stroke (26-28). In vitro, raloxifene 
plays a role in the modulation of bone homeostasis by inhibiting osteoclastogenesis 
and bone resorption, stimulating osteoblast activity, and inhibiting interleukin 1β, 
interleukin 6 and TNF-α (29). In vivo studies also demonstrate positive effects of the 
drug on the maintenance of mineral bone density of the lumbar spine, femoral neck 
(17,18,28) and tibia (30). Those studies also reported a decrease in biochemical markers 
of bone remodeling, such as osteocalcin, alkaline phosphatase, interleukin 1β, and 
interleukin 6 (17,18), as well as a reduced risk of microfractures (28). There is evidence 
that the effi cacy of raloxifene is similar in the bones of male rats and ovariectomized 
female rats (15,31), with an increased expression of selective bone turnover markers 
in ovariectomized female rats during the alveolar healing process (20). Conversely, 
raloxifene replacement has proved unable to recover the estrogen-defi cient states 
(20,32). Thus, the action of the drug does not depend on sex.
Even though the effects of raloxifene in bone metabolism have been widely 
recognized, the results obtained in the present study have shown that the drug does not 
prevent MFL-induced ABL. This result may be explained by the evidence suggesting 
that bone mineral density of spine and hip bones cannot be used as predictors of 
maxillary bone density (33,34). The hypothesis of site-specifi c bone remodeling 
formulated by Podenphant and Engel (35) may also help interpret the results of the 
present study. Those authors investigated 24 different sites of the skeleton and observed 
that bone formation undergoes considerable regional variations. This hypothesis was 
confi rmed by Verna et al. (36), who compared the parameters of bone remodeling of the 
mandible with those of the iliac crest. Titanium implants represent a good example of 
site specifi city in bone remodeling, with data showing that 76% of failure in orthopedic 
implants occur in patients with osteoporosis (37), while the risk of failure in dental 
implants does not seem to be higher for patients with osteoporosis (38).
The effects of other drugs, such as bifosfonates and doxycycline, in ABL have 
been investigated previously. Bifosfonates, drugs prescribed in the treatment and 
prevention of osteoporosis, have been shown by several studies to decrease ABL 
after MFS in rats (4,10,12). The results found by Yaffe et al. (4,12) demonstrate a 
decrease in ABL after bifosfonate therapy. Doxycycline was also shown to be able to 
prevent MFS-induced ABL in a rat model, according to Grevstad (9). Nevertheless, 
it is important to carefully consider the methodology adopted in the evaluation of 
ABL in each study.
Different methods have been proposed to study ABL in animal models, with 
some methodologies evaluating the mineralized matrix (12-14,39,40), others evaluating 
histological sections (9,10), and others evaluating linear distance measurements (39-
41). Yet, all these methods were shown to have limitations (12,39,40). Yaffe et al. (14) 
demonstrated the effect of alendronate on preventing ABL using high resolution X-ray 
microradiography analysis. However, no signifi cant differences were observed when 
ABL was assessed using measurements of the exposed root area. 
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Further studies are needed to assess the effect of raloxifene in mandibular bones in 
terms of bone mineral density, decrease in bone turnover biomarkers, or positive changes 
in cell counts. Further knowledge of these aspects is relevant for the aim of maintaining 
alveolar bone.
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